Company profile ALEC

Alector Inc
we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.
Quarter analysis & expected interest

There is not enough data for Alector, Inc. to provide analysis

Correlation between past revenue and Alector, Inc. search interest

There is not enough data for Alector, Inc. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector, Inc. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector neurodegenerative diseases to provide analysis

Correlation between past revenue and Alector neurodegenerative diseases search interest

There is not enough data for Alector neurodegenerative diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector neurodegenerative diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector clinical trials to provide analysis

Correlation between past revenue and Alector clinical trials search interest

There is not enough data for Alector clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector AL001 to provide analysis

Correlation between past revenue and Alector AL001 search interest

There is not enough data for Alector AL001 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector AL001 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector AL101 to provide analysis

Correlation between past revenue and Alector AL101 search interest

There is not enough data for Alector AL101 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector AL101 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector collaboration agreements to provide analysis

Correlation between past revenue and Alector collaboration agreements search interest

There is not enough data for Alector collaboration agreements to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector collaboration agreements to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 14:09:59.

After 39 days of this quarter the interest is at 74.0. Based on that we can calculate that during remaining 52 days it will total up to 173.0.
Alector stock price expected interest is significantly higher compared to previous quarter (+592.0%) and same quarter last year (+765.0%).

YearQ1Q2Q3Q4
2019122
184
50.8% QoQ
104
-43.5% QoQ
100
-3.8% QoQ
2020 269
120.5% YoY 169.0% QoQ
100
-45.7% YoY -62.8% QoQ
344
230.8% YoY 244.0% QoQ
248
148.0% YoY -27.9% QoQ
2021 263
-2.2% YoY 6.0% QoQ
141
41.0% YoY -46.4% QoQ
227
-34.0% YoY 61.0% QoQ
138
-44.4% YoY -39.2% QoQ
2022 152
-42.2% YoY 10.1% QoQ
165
17.0% YoY 8.6% QoQ
106
-53.3% YoY -35.8% QoQ
102
-26.1% YoY -3.8% QoQ
2023 20
-86.8% YoY -80.4% QoQ
45
-72.7% YoY 125.0% QoQ
18
-83.0% YoY -60.0% QoQ
25
-75.5% YoY 38.9% QoQ
2024 74
270.0% YoY 196.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Alector stock price search interestLast update: February 08 2024 14:09:59.
Correlation coefficient between keyword and revenue is -0.17
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:10:00.

The average 5 years interest of Alector stock price was 11.29 per week.
The last year interest of Alector stock price compared to the last 5 years has changed by -72.36%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -71.84%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector career opportunities to provide analysis

Correlation between past revenue and Alector career opportunities search interest

There is not enough data for Alector career opportunities to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector career opportunities to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector patient testimonials to provide analysis

Correlation between past revenue and Alector patient testimonials search interest

There is not enough data for Alector patient testimonials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector patient testimonials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alector near me to provide analysis

Correlation between past revenue and Alector near me search interest

There is not enough data for Alector near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alector near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ALEC
Earnings date: 2024-02-26 After close
Company name: Alector Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-10-16T04:30:00-07:00

GlobeNewswire
Alector Announces Pricing of Underwritten Offering

2026-10-15T10:57:01.62385041Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8

2026-10-14T15:45:41.822379346Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8

2026-10-13T08:00:00-07:00

Earnings Call Transcripts
Alector Pipeline Webinar: Advancing Next Generation Medicines for Neurodegeneration - ALECTOR INC

2026-10-07T13:05:00-07:00

GlobeNewswire
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

2026-10-06T17:01:56.908603688Z

Analyst Upgrades
Morgan Stanley Maintains Underweight on Alector, Raises Price Target to $3

2026-09-15T07:00:00-04:00

Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - ALECTOR INC

2026-09-15T07:00:00-04:00

Earnings Call Transcripts
Alector - 1773720 - ALECTOR INC

2026-09-15T07:00:00-04:00

Earnings Call Transcripts
Alector - 1773720 - ALECTOR INC

2026-09-03T13:05:00-07:00

GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences

2026-08-06T13:05:00-07:00

GlobeNewswire
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-05-07T20:05:00Z

GlobeNewswire
Alector Reports First Quarter 2026 Financial Results and Provides Business Update

2026-04-29T20:05:00Z

GlobeNewswire
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

2026-04-15T17:53:12Z

Analyst Upgrades
This Cloudflare Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

2026-04-15T12:08:04Z

Analyst Upgrades
Cantor Fitzgerald Upgrades Alector to Overweight